Profusa, Inc. Regains Nasdaq Compliance; Placed on One-Year Monitor

What Happened
Profusa, Inc. announced that on September 9, 2026 Nasdaq confirmed the company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule) and Listing Rule 5550(b)(1) (the Equity Rule). Nasdaq also informed Profusa that, under Nasdaq Listing Rule 5815(d)(4)(B), the company will be subject to a one-year Mandatory Panel Monitor (the Monitoring Period). The company filed the Form 8-K reporting this action on September 15, 2026.

Key Details

• Nasdaq Compliance Determination letter dated September 9, 2026 confirmed compliance with Rule 5550(a)(2) and Rule 5550(b)(1).
• Profusa will be subject to a one-year Mandatory Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B).
• If Nasdaq finds Profusa out of compliance with the Equity Rule during the Monitoring Period, Nasdaq will issue a Staff Delisting Determination promptly and will not permit a plan of compliance, additional time to regain compliance, or a cure period under Nasdaq Listing Rule 5810(c)(2)/(3).
• Profusa may appeal any Staff Delisting Determination under the procedures in Nasdaq Listing Rule 5815.

Why It Matters
Being returned to compliance removes the immediate threat of delisting, but the one-year Mandatory Panel Monitor increases regulatory scrutiny and raises the stakes for any future compliance shortfalls. If the company slips out of compliance again during this period, Nasdaq’s expedited delisting process could reduce the time and options available to cure the deficiency, which could affect the stock’s listing status, liquidity, and investor value. The company stated it will continue to monitor compliance and included standard forward-looking statement cautions.